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Uncoupling protein 2 mRNA down-regulation in women treated with glucocorticoids Obesity is frequently associated with insulin resistance and cardiovascular disease, and in this condition PAI-1 levels are often increased. The 4Ga5G polymorphism of PAI-1 may in¯uence PAI-1 levels in diseases associated with atherosclerosis and thrombotic risk. We studied the relationship between anthropometric and endocrine-metabolic parameters and PAI-1 concentration in 93 obese patients and 79 lean controls. In obese patients PAI-1 antigen (PAI-1:Ag) levels were signi®cantly increased (p`0.00001), and associated with BMI, systolic blood pressure, insulin, summatory values of insulin from OGTT (SIns) and triglycerides (TG) on multivariate analysis, and higher in males (p 0.005). Patients with central obesity disclosed a signi®cant increase in PAI-1:Ag compared to both patients with peripheral obesity (p 0.0027) and normal subjects (p`0.00001), whereas no difference was seen between patients with peripheral obesity and controls. Only in patients with central adiposity were PAI-1:Ag levels associated with insulin, SIns and TG on multivariate analysis. The 4Ga5G polymorphism was a determinant of PAI-1:Ag levels in obese subjects but not in lean controls, with higher values in the 4Ga4G than in the 5Ga5G homozygous patients (p 0.029), and intermediate in the heterozygous ones. Only in 4G allele obese carriers were PAI-1:Ag levels correlated with anthropometric and endocrine-metabolic parameters, and signi®cantly associated with waist-to-hip ratio (WHR) (p 0.023) in 4Ga4G patients, and with BMI (p 0.05), insulin (p 0.035), and TG (p 0.011) in 4Ga5G patients on multivariate analysis. The relationship between genotype and PAI-1 concentration was still present only in patients with central obesity, with higher levels in the 4Ga4G than in the 5Ga5G patients (p 0.024). Considering each genotype subset of patients with central adiposity, PAI-1:Ag levels were signi®cantly increased compared to their non obese polymorphic counterparts. On the other hand, patients with peripheral obesity showed PAI-1:Ag values similar to controls. Our data demonstrate that the degree of insulin-resistance is related to PAI-1 in obese patients, particularly in those with central obesity. Moreover, the 4Ga5G polymorphism of PAI-1 may signi®cantly in¯uence PAI-1 expression in obesity, where it seems to play a determinant role in subjects with central but not peripheral adiposity. Since central obesity is linked to a higher risk for cardiovascular disease, the effects of the 4Ga5G polymorphism on PAI-1 concentration may further enhance this risk.
